Free Trial

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Sells $60,016.00 in Stock

Charles River Laboratories International logo with Medical background

Key Points

  • Charles River Laboratories' EVP Joseph W. Laplume sold 400 shares of stock for $60,016.00, reducing his ownership by 1.58% to a total of 24,916 shares valued at approximately $3.74 million.
  • The company's stock price fell $0.71 to $149.07, with a market cap of $7.32 billion and a current PE ratio of -112.08.
  • In its latest earnings report, Charles River Laboratories surpassed estimates with an EPS of $3.12, driven by revenue of $1.03 billion, marking a 0.6% year-over-year increase.
  • Looking to export and analyze Charles River Laboratories International data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Joseph W. Laplume sold 400 shares of the stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $150.04, for a total value of $60,016.00. Following the transaction, the executive vice president owned 24,916 shares in the company, valued at approximately $3,738,396.64. This trade represents a 1.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Charles River Laboratories International Trading Up 2.4%

CRL traded up $3.57 during midday trading on Tuesday, hitting $152.50. 267,323 shares of the company were exchanged, compared to its average volume of 1,278,493. The firm has a market capitalization of $7.50 billion, a P/E ratio of -114.55, a P/E/G ratio of 4.74 and a beta of 1.48. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The firm's 50 day moving average price is $155.83 and its 200-day moving average price is $149.00. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%. The business's quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.80 EPS. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent research reports. Robert W. Baird raised their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday, May 8th. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their price target for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their price objective for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. Barclays increased their price objective on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $175.69.

Get Our Latest Research Report on Charles River Laboratories International

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Rothschild Investment LLC lifted its position in shares of Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares during the period. Brooklyn Investment Group lifted its position in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after acquiring an additional 86 shares during the period. Cromwell Holdings LLC lifted its position in shares of Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company's stock valued at $27,000 after acquiring an additional 152 shares during the period. Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International during the 2nd quarter valued at $29,000. Finally, Optiver Holding B.V. bought a new stake in Charles River Laboratories International during the 4th quarter valued at $37,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

(Get Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Should You Invest $1,000 in Charles River Laboratories International Right Now?

Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines